CompanyGraph
Shanghai Miracure Pharmaceuticals Co., Ltd.
688373 · SSE · China
micurxchina.comFinancials as of FY2025
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- ScaleRevenue is $24.53M, lower than 95% of all stocks globally
- FinancialsAltman Z-Score 0.57: distress zone
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
4.04BCNY602.42M · vs all stocks (USD)
Revenue (TTM)
164.33MCNY24.53M · vs all stocks (USD)
Profit Margin
-85.50%Beta
0.4150xvs all stocks
52-Week Change
-36.40%vs all stocks
Market Capitalization
4.04BCNY602.42M · vs all stocks (USD)
Enterprise Value
3.52BCNY526.01M · vs all stocks (USD)
Price to Sales (TTM)
23.84xPrice to Book (MRQ)
19.70xEnterprise to Revenue
21.44xEnterprise to EBITDA
-24.10xGross Margin
87.49%Profit Margin
-85.50%Operating Margin
-39.63%Return on Assets (TTM)
-13.21%Return on Equity (TTM)
-58.99%Revenue (TTM)
164.33MCNY24.53M · vs all stocks (USD)
Revenue per Share (TTM)
0.2580CNYUpdated Sep 22, 2026Quarterly Revenue Growth
40.60%Gross Profit (TTM)
141.00MCNY21.05M · vs all stocks (USD)
EBITDA (TTM)
-146.21MCNY-21.82M · vs all stocks (USD)
Net Income (TTM)
-140.50MCNY-20.97M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
42.91%Operating Cash Flow (TTM)
-115.87MCNY-17.30M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-78.96MCNY-11.79M · vs all stocks (USD)
Payout Ratio
0.00%Revenue
141.77MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
21.53MCNYFY2025 · Dec 31, 2025Gross Profit
120.24MCNYFY2025 · Dec 31, 2025Operating Income
-244.30MCNY-36.47M · vs all stocks (USD)
Pre-tax Income
-245.57MCNYFY2025 · Dec 31, 2025Income Tax Expense
-3.95MCNYFY2025 · Dec 31, 2025Net Income
-241.61MCNYFY2025 · Dec 31, 2025EBIT
-232.67MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
-223.93MCNYFY2025 · Dec 31, 2025Research & Development
213.93MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
86.41MCNYFY2025 · Dec 31, 2025Other Operating Expenses
538.15KCNYFY2025 · Dec 31, 2025Non-operating Interest Income
2.41MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
12.89MCNYFY2025 · Dec 31, 2025Net Income from Continuing Operations
-241.61MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
-235.98MCNYFY2025 · Dec 31, 2025Free Cash Flow
-236.52MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
294.94MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-241.61MCNYFY2025 · Dec 31, 2025Stock-based Compensation
14.47MCNYFY2025 · Dec 31, 2025Other Non-cash Items
15.74MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-27.26MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
2.68MCNYFY2025 · Dec 31, 2025Capital Expenditures
-545.30KCNYFY2025 · Dec 31, 2025Purchase of Investments
-2.50BCNYFY2025 · Dec 31, 2025Sale of Investments
2.67BCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
165.49MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
205.70MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-116.46MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-8.88MCNYFY2025 · Dec 31, 2025Other Financing Charges
-12.06MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
68.31MCNYFY2025 · Dec 31, 2025Shares Outstanding
656.23MSharesUpdated Sep 22, 2026Float Shares
422.47MSharesUpdated Sep 22, 2026% Held by Insiders
43.98%vs all stocks
% Held by Institutions
2.85%vs all stocks
Total Cash (MRQ)
393.58MCNY58.75M · vs all stocks (USD)
Total Cash per Share (MRQ)
0.6000CNYUpdated Sep 22, 2026Total Debt (MRQ)
360.70MCNY53.84M · vs all stocks (USD)
Total Debt to Equity (MRQ)
2.21xCurrent Ratio (MRQ)
2.17xBook Value per Share (MRQ)
0.3030CNYUpdated Sep 22, 2026Total Assets
705.09MCNY105.25M · vs all stocks (USD)
Total Current Assets
622.46MCNYFY2025 · Dec 31, 2025Total Liabilities
499.55MCNYFY2025 · Dec 31, 2025Total Non-current Assets
82.63MCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
275.17MCNYFY2025 · Dec 31, 2025Total Current Liabilities
224.38MCNYFY2025 · Dec 31, 2025Cash
316.02MCNYFY2025 · Dec 31, 2025Cash Equivalents
79.66KCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
316.10MCNYFY2025 · Dec 31, 2025Other Short-term Investments
135.54MCNYFY2025 · Dec 31, 2025Accounts Receivable
37.96MCNYFY2025 · Dec 31, 2025Inventory
50.25MCNYFY2025 · Dec 31, 2025Accounts Payable
80.30MCNYFY2025 · Dec 31, 2025Short-term Debt
106.21MCNYFY2025 · Dec 31, 2025Other Current Liabilities
28.30KCNYFY2025 · Dec 31, 2025Long-term Debt
273.42MCNYFY2025 · Dec 31, 2025Common Stock (Book)
656.23MCNYFY2025 · Dec 31, 2025Retained Earnings
-2.05BCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
205.54MCNY30.68M · vs all stocks (USD)
52-Week Low
4.09CNYUpdated Sep 22, 202652-Week High
10.31CNYUpdated Sep 22, 202652-Week Change
-36.40%vs all stocks
Beta
0.4150xvs all stocks
50-Day MA
5.23CNYUpdated Sep 22, 2026200-Day MA
5.66CNYUpdated Sep 22, 2026Avg 10-Day Volume
9.25MSharesUpdated Sep 22, 2026Avg 30-Day Volume
17.57MSharesUpdated Sep 22, 2026Diluted EPS (TTM)
-0.2200CNYUpdated Sep 22, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.87Profit Margin: -0.85
Significant cash reserves alongside high leverageNotable
Cash (USD): 58,748,950.997Total Debt (USD): 53,841,655.564Debt-to-Equity: 2.21
Looks liquid, but the distress score says otherwiseNotable
Current Ratio: 2.17Altman Z-Score: 0.57
Financial Health
Altman Z-Score 0.57: distress zoneCritical
Altman Z-Score: 0.57
High structural barrier to entryNotable
Barrier to Entry: 16.80
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Scale
Revenue is $24.53M, lower than 95% of all stocks globallySignificant
Revenue (USD): 24,529,985.716Global P5: 35,820,060.775
Companies that share the same coordination system — how they create, deliver, or capture value.
Hefei Lifeon Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Beijing Science Sun Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Jinling Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai Xiao Feng Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Genfit S.A.
Tier 1ProductionApproval-Gated PipelineRuleRisk
FDC Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Qianjiang Yongan Pharmaceutical Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Valneva SE
Tier 1ProductionApproval-Gated PipelineRuleRisk
Shenzhen Neptunus Bioengineering Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Beijing Bohui Innovation Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow